Results 201 to 210 of about 15,140 (255)

Chromoblastomycosis is curable with DAT therapy (debulking, intralesional amphotericin B, oral terbinafine); case series of 16 patients.

Indian J Pharmacol
Ranawaka RR, Abeywickrama V.
europepmc   +1 more source

Genomic epidemiology of emerging terbinafine-resistant Trichophyton indotineae

Rhodes J, Hui ST, Dellière S, Summerbell RC, Scott JA, Kaur A, Barton RC, Leitao R, Hemmings S, Goiriz R, Lambourne J, Farrer RA, Schelenz S, Hay RJ, Borman AM, Chowdhary A, Abdolrasouli A, Fisher MC.   +17 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Terbinafine-Resistant Dermatophytes and the Presence of Trichophyton indotineae in North America

Journal of Clinical Microbiology, 2023
Dermatophytes are common causes of skin, hair, and nail infections in humans. The most common species causing infections in humans are Trichophyton rubrum, Trichophyton mentagrophytes, and Trichophyton interdigitale.
C. Cañete-Gibas, J. Mele, Hoja P. Patterson, Carmita J. Sanders, Dora Ferrer, Victor Garcia, H. Fan, M. David, N. Wiederhold   +8 more
semanticscholar   +1 more source

A new bioassay for terbinafine [PDF]

European Journal of Clinical Microbiology & Infectious Diseases, 1988
A simple, sensitive and specific agar diffusion bioassay for the antifungal agent terbinafine is described. Using a strain of Aspergillus flavus as the test organism, terbinafine at concentrations ranging from 0.2 microgram/ml to 6.4 micrograms/ml could be measured in serum.
Donald Armstrong, H J Schmitt, M. Hauser, E. M. Bernard   +3 more
openaire   +2 more sources

Hypersensitivity reaction to terbinafine [PDF]

Journal of the American Academy of Dermatology, 1997
3. TomsickRS.Thephenytoinsyndrome.Cutis 1983;32:53541. 4. Stanley J, Fallon-Pellicci V. Phenytoin hypersensitivity reaction. Arch Dermatol 1978;114:1350-3. 5. Parker WA, Shearer CA. Phenytoin hepatotoxicity: a case report and review. Neurology 1979;29:175-8. 6. McCarthy 1_2, Aguilar JC, Ransburg R. Fatal benign phenytoin lymphadenopathy. Arch Intem Med
Neil H. Shear, Jerome B. Kopstein, Aditya K. Gupta   +2 more
openaire   +2 more sources

Green formulation, characterization, antifungal and biological safety evaluation of terbinafine HCl niosomes and niosomal gels manufactured by eco-friendly green method

Journal of Biomaterials Science. Polymer Edition, 2022
Terbinafine (TER) is a promising candidate medication for the topical treatment of fungal infections. However, its solubility in water and skin permeability are limited. To overcome these limitations, a Terbinafine niosome and niosomal gel was developed.
K. Morteza-Semnani, M. Saeedi, J. Akbari, Shakiba Hedayati, S. M. H. Hashemi, Seyyed Mobin Rahimnia, A. Babaei, M. Ghazanfari, I. Haghani, M. Hedayati   +9 more
semanticscholar   +1 more source

The Emerging Terbinafine-Resistant Trichophyton Epidemic: What Is the Role of Antifungal Susceptibility Testing?

Dermatology, 2021
Background: Dermatophytosis is commonly encountered in the dermatological clinics. The main aetiological agents in dermatophytosis of skin and nails in humans are Trichophyton (T.) rubrum, T. mentagrophytes and T. interdigitale (former T.
Julia J. Shen, M. Arendrup, S. Verma, D. Saunte   +3 more
semanticscholar   +1 more source

Terbinafine: An update

Journal of the American Academy of Dermatology, 1997
Oral terbinafine was first introduced in the United Kingdom in February 1991 and was approved for the treatment of onychomycosis in the United States in May 1996. It is estimated that 4 million patients worldwide have been treated with oral terbinafine as of December 1996.
Neil H. Shear, Aditya K. Gupta
openaire   +3 more sources